This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Invokamet

Johnson & Johnson

Drug Names(s): canagliflozin and immediate release metformin fixed dose combination (FDC), canagliflozin/metformin HC, Vokanamet

Description: Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor.

Metformin is a first-line pharmacotherapy that can be used alone or with other medications, including insulin, to treat type 2 diabetes. Metformin lowers blood glucose levels by decreasing the amount of glucose made by the liver.

As of January 2013, Johnson & Johnson is now disclosing that it is developing a fixed dose combination (FDC) of canaglifozin and Glumetza (extended release metformin), found here.

Deal Structure: In Europe and the U.S., canagliflozin is licensed to Johnson & Johnson.

Partners: Mitsubishi Tanabe Pharma Corporation


Invokamet News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug